Evaluation of topical brinzolamide switched from dorzolamide for glaucoma

Japanese Journal of Clinical Ophthalmology

Volumn 59, Issue 2, 2005, Pages 215-219

  Hasegawa, Kou ^a   Takahashi, Tomoko ^a   Kawase, Kazuhide ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSED ANGLE GLAUCOMA; DRUG INSTILLATION; EVALUATION; EYE IRRITATION; EYELID; FEMALE; GLAUCOMA; HUMAN; MALE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; SIDE EFFECT;

EID: 14944340199     PISSN: 03705579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kitazawa Y, Azuma I, Iwata K et al: Dorzolamide, a topical carbonic anhydrase inhibiter; a two-week dose response study in patients with glaucoma or ocular hypertension. J Glaucoma 3: 275-279, 1994
2. The MK-507 Clinical Study Group: Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J Glaucoma 4: 6-10, 1995
3. Silver LH and the Brinzolamide Primary Therapy Study Group: Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 126: 400-408, 1998
4. Michaud J, Friren B and the International Brinzolamide Adjunctive Study Group: Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132: 235-243, 2001
5. Barnebey H, Kwok S: Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 22: 1204-1212, 2000